Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H1 2018, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 6, 48, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 4 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Addex Therapeutics Ltd
AFFiRiS AG
Annexon Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
BrainStorm Cell Therapeutics Inc
Celon Pharma SA
Chong Kun Dang Pharmaceutical Corp
Evotec AG
Exicure Inc
F. Hoffmann-La Roche Ltd
Genervon Biopharmaceuticals LLC
Horizon Pharma Plc
Immungenetics AG
InMed Pharmaceuticals Inc
Kadmon Corp LLC
Living Cell Technologies Ltd
Medesis Pharma SA
MindImmune Therapeutics Inc
Mitochon Pharmaceuticals Inc
Neurimmune Holding AG
Neurocrine Biosciences Inc
NeuroNascent Inc
New World Laboratories Inc
nLife Therapeutics SL
Novartis AG
Omeros Corp
Oryzon Genomics SA
Priavoid GmbH
Probiodrug AG
ProQR Therapeutics NV
PTC Therapeutics Inc
QR Pharma Inc
reMYND NV
Shire Plc
SOM Biotech SL
Spark Therapeutics Inc
Stealth BioTherapeutics Inc
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Ultragenyx Pharmaceutical Inc
UniQure NV
Vaccinex Inc
Vertex Pharmaceuticals Inc
Vitality Biopharma Inc
Voyager Therapeutics Inc
Vybion Inc
WAVE Life Sciences Ltd